Bing Cai, PhD

The authors describe some cases of container closure design flaws and actions taken by FDA to mitigate safety risks and increase patient acceptability.

Companies may potentially accelerate the approval of generic drugs by avoiding deficiencies in ANDA submissions.

The authors of "Common Deficiencies in ANDAs for Dermatologic Drug Products" provide some examples of commonly cited deficiencies cited by FDA.